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Abstract:  
The aging of the population makes the problematic of inflammatory bowel disease in the elderly 
of increasing concern. The complexity of this age group, with its comorbidities, changing 
physiology and functional status, risk of polypharmacy and adverse effects, presents the caring 
physician with unique challenges in the management of this chronic condition. Current 
therapeutic algorithms may not be applicable in the elderly population and require 
modifications that account for age. This review examines what is already known about 
inflammatory bowel disease in the elderly and highlights existing gaps in understanding that 
require further investigation as a framework for development of clinical guidelines suited to 
this distinctive population.  
Keywords: Inflammatory bowel disease (IBD), Crohn’s disease, Ulcerative colitis, elderly-
onset IBD, late-onset IBD and long-standing IBD, epidemiology, pathophysiology, genetics, 
immunology, immunosenescence, environmental factors, gut microbiome, clinical 
presentation, differential diagnosis, therapy, aging.  
Resumo:  
O envelhecimento da população torna a problemática da doença inflamatória intestinal no 
paciente idoso cada vez mais relevante. A complexidade desta faixa etária, com as suas 
comorbilidades, alterações fisiológicas e detrimento funcional, assim como o risco acrescido 
de polifarmácia e iatrogenia colocam desafios acrescidos à abordagem médica desta doença 
crónica. Os algoritmos terapêuticos correntemente em prática frequentemente são difíceis de 
aplicar na população idosa sendo necessárias modificações que tomem em consideração a 
idade. Este artigo de revisão propõe examinar o conhecimento já existente à cerca da doença 
inflamatória intestinal e sublinhar áreas de compreensão que necessitam de investigação 
acrescida no sentido de permitir a criação de normas de orientação clínica adaptadas a esta 
população distinta.  
Palavras chave: Doença inflamatória intestinal (DII), doença de Crohn, colite ulcerosa, DII de 
longa duração, DII de início tardio, DII geriátrica, epidemiologia, fisiopatologia, genética, 
imunologia, imunossenescência, fatores ambientais, microbioma intestinal, apresentação 
clínica, diagnóstico diferencial, terapia, envelhecimento. 
 
O Trabalho final exprime a opinião do autor e não da FML. 
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Resumo do Trabalho: 
A doença inflamatória intestinal é uma doença crónica cuja história natural determina, pela sua 
gravidade e duração, custos socioeconómicos consideráveis. O número de doentes com idade 
superior a 65 anos, portadores de DII, é cada vez maior, dado o envelhecimento da população 
e o aumento de incidência da doença. A DII no doente idoso afeta dois grupos populacionais 
diferentes. Um grupo no qual o diagnóstico foi feito na infância ou em idade adulta (i.e. DII de 
longa duração) e outro constituído pelos doentes com diagnóstico recente (i.e. DII geriátrica). 
O presente trabalho pretende sumarizar a literatura existente relativamente às características 
destas duas entidades, providenciar informação para a adequação da estratégia terapêutica à 
população idosa com DII e identificar áreas de conhecimento que necessitem de mais 
investigação. 
A evidência, relativamente às diferenças entre DII de longa duração e geriátrica, é contraditória, 
havendo estudos que indicam fenótipos díspares e outros que apontam para características 
similares. No entanto, é importante considerar que o doente idoso é complexo em si mesmo, 
não apenas pelas comorbilidades de que padece, mas também pela polifarmácia inerente à sua 
condição de fragilidade. Assim sendo, quaisquer interpretações sobre a gravidade de doença ou 
suas manifestações sintomáticas têm de ser contextualizadas face ao doente em questão. A 
evidência parece apontar para uma menor severidade da DII geriátrica, com menor gravidade 
sintomática, ausência de história familiar e diferente localização no trato gastrointestinal, 
comparativamente à DII de longa duração.  
O diagnóstico diferencial é dificultado no doente idoso não só pelos sintomas frequentemente 
indolentes e inespecíficos da DII geriátrica, mas também pelo facto de o leque de doenças a 
considerar nesta faixa etária ser considerável, incluindo desde a doença diverticular, a colite 
isquémica, a colite microscópica, a colite por anti-inflamatórios não-esteróides e doença 
maligna. A dificuldade do diagnóstico diferencial é assim uma importante razão para o atraso 
no diagnóstico de DII no doente idoso, o qual pode ir até seis anos, comparativamente ao doente 
jovem. 
O idoso com DII tem um risco acrescido de desenvolver vários tipos de cancro e 
consequentemente necessita de vigilância regular e de um rastreio completo antes de iniciar 
qualquer terapia imunossupressora. Nos doentes com DII, o cancro colo-retal (CCR) surge em 
idades mais jovens do que na população geral. Consideram-se como fatores de risco para CCR 
nos doentes com DII o sexo masculino, a idade de diagnóstico mais jovem e a colite extensa. 
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Para além do risco inerente à patofisiologia da doença em si, os fármacos utilizados no 
tratamento da DII, nomeadamente os imunomoduladores e os agentes biológicos, estão também 
associados a um aumento de risco de cancro. Foram reportados casos de carcinoma do trato 
urinário e da tiróide com o uso de imunomoduladores como as tiopurinas, assim como um 
aumento do número de casos de cancro da pele não-melanoma. O tratamento dos doentes com 
DII que concomitantemente apresentam uma neoplasia é complexo, dado o risco de proliferação 
tumoral associado ao uso da medicação imunossupressora. O consenso atual nestas 
circunstâncias envolve a cessação das tiopurinas, dos inibidores da calcineurina e dos agentes 
anti-TNF alfa até o tratamento oncológico terminar. Crises ligeiras de DII podem ser tratadas 
com 5-aminosalicilatos e ou corticosteroides locais. O metotrexato, os agentes anti-TNF alfa e 
os corticosteróides sistémicos de curta duração devem ser utilizados em crises mais graves. 
Na população de idosos, com idade superior a 65 anos, 20% sofre de pelo menos cinco doenças 
crónicas. A imunosenescência, que corresponde à diminuição da função imunológica com a 
idade, contribui para uma menor vigilância antitumoral, um aumento da suscetibilidade 
infeciosa e uma redução da resposta à vacinação. Estes factores, inerentes à idade geriátrica, 
contribuem para a diminuição da performance status do idoso e perpetuam um estado de 
fragilidade, que se reveste de particular relevância no doente com doença intestinal 
inflamatória. Idosos com DII sofrem mais frequentemente de doença cardiovascular, doença 
pulmonar e de diabetes mellitus. Uma implicação direta deste contexto geriátrico é a 
polifarmácia e a iatrogenia, com consequências em termos de morbilidade e mortalidade.  
Quando hospitalizados, os doentes idosos com DII têm uma mortalidade superior à dos doentes 
mais jovens, mesmo após ajustamento para as comorbilidades e presença de complicações, 
demonstrando que a idade é um fator de risco independente de mortalidade. Em termos de 
resultados cirúrgicos, os doentes com idade superior a 60 anos têm tempo de internamento mais 
prolongado, com complicações acrescidas. Estas observações demonstram a complexidade do 
doente idoso, sendo necessário uma adaptação dos regimes terapêuticos a este grupo etário, 
para prevenir os internamentos, uma vigilância acrescida para evitar as complicações e a 
necessidade de cirurgia. 
A decisão terapêutica no idoso com DII é complexa e influenciada por múltiplas variáveis 
associadas ao processo de senescência. Nesta faixa etária surge uma diminuição da função 
imunitária designada de imunosenescência, com desequilíbrios das respostas Th1 e Th2 e 
aumento do risco de infeção e doença maligna. A nível fisiológico, enquanto a composição 
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corporal em água, massa magra e volume extracelular diminui, a massa gorda aumenta, 
alterando o volume de distribuição de vários fármacos com implicações em termos de índice 
terapêutico. Por outro lado, a diminuição da taxa de filtração glomerular assim como a redução 
do fluxo sanguíneo esplâncnico e hepático, afetam a depuração dos fármacos. Por todos estes 
motivos, os regimes terapêuticos convencionais devem ser ajustados face à realidade do doente 
idoso, dando primazia à estratégia "start low and go slow".  
As comorbilidades neste grupo etário frequentemente condicionam a prescrição. Um exemplo 
pertinente é o risco de hiperglicemia nos doentes diabéticos com a utilização de 
corticosteróides. Esta classe terapêutica é conhecida pelo seu perfil de efeitos secundários, o 
que no doente idoso tem particular relevância, nomeadamente dislipidémia, hipertensão, 
osteoporose, depressão e risco infecioso. 
Nesta faixa etária as múltiplas comorbilidades e a polifarmácia associada representam um risco 
acrescido de interações medicamentosas sendo assim essencial a revisão minuciosa de toda a 
medicações do doente de forma a evitar reações adversas. 
Perante a realidade exposta, os objetivos terapêuticos no doente idoso terão necessariamente de 
ser diferentes. O controlo sintomático através de um regime tolerado pelo doente, a 
simplificação da medicação tendo em conta as interações medicamentosas e os custos 
contribuem para melhorar a compliance e os resultados terapêuticos. Os aspetos da qualidade 
de vida do doente devem também ser abordados, não negligenciando sintomas como a 
incontinência, a disfunção sexual e a fadiga.   
Os padrões de prescrição nos doentes com DII variam consoante a idade. A sulfassalazina e os 
corticosteróides são os fármacos mais prescritos nos idosos. Os biológicos e os 
imunomoduladores são significativamente menos, contrariamente ao que acontece nos doentes 
jovens. A aparente menor gravidade da DII geriátrica, assim como o receio de maiores efeitos 
adversos, poderá justificar a baixa utilização de potentes fármacos imunossupressores neste 
grupo etário.  
O tratamento adequado da DII depende de fatores como a severidade da doença, a sua 
localização, a sua extensão, a resposta a tratamentos prévios, as comorbilidades e compliance 
do doente. A gravidade da colite ulderosa (CU) é avaliada pelos critérios modificados de 
Truelove e Witts e dividida em ligeira, moderada a grave. A doença de Crohn por sua vez é 
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classificada de acordo com os critérios de Montreal em termos de distribuição e em termos de 
gravidade pelo índice de actividade da doença de Crohn (CDAI).  
Os 5-aminosalicilatos são considerados seguros e eficazes no tratamento de colite ulcerosa 
ligeira (CU) a moderada em doentes com DII independentemente da idade. Estes agentes não 
têm utilidade comprovada no tratamento da Doença de Crohn (DC).  
Os corticosteroides, ao contrário do que acontece em doentes mais jovens, são usados na 
população idosa com DII não apenas para a indução de resposta, mas também no tratamento de 
manutenção, apesar das suas conhecidas complicações. O tratamento continuado com esta 
classe terapêutica sem um plano de redução progressiva e eventual cessação pode levar a um 
aumento de mortalidade destes doentes. Torna-se, portanto, crucial a existência de um follow-
up periódico com revisão terapêutica em cada sessão. Atualmente, o uso desta classe 
farmacológica está indicado na indução de remissão da DC ligeira (com budenosido oral), 
moderada e grave (com corticosteroides sistémicos). Na CU, corticoides sistémicos são 
apropriados em doentes com doença moderada a severa ou com doença ligeira que não 
respondem aos 5-aminosalicilatos.  
A azatioprina, a 6-mercaptopurina, a ciclosporina e o metotrexato são os quatro 
imunomoduladores mais frequentemente utilizados na DII. De um modo geral, não existem 
diferenças em termos de eficácia e toxicidade entre doentes jovens e idosos. São eficazes no 
tratamento de manutenção da CU ligeira a moderada refratária aos 5-aminosalicilatos assim 
como em doentes dependentes de corticosteroides. A ciclosporina é útil também no tratamento 
da CU ativa e refratária aos corticosteroides sistémicos. Na DC ativa, os imunomoduladores 
(exceto a ciclosporina) podem ser utilizados como complemento à terapêutica ou como agentes 
poupadores de corticosteroides. Esta classe farmacológica é essencial na manutenção da 
remissão na DC, seja localizada ou extensa, ou dependente de corticosteroides.  
Os agentes anti-TNF alfa, também designados de agentes biológicos, são empregues na doença 
de Crohn e colite ulcerosa moderada a grave tanto na fase de indução de resposta como na fase 
de manutenção terapêutica. Estudos recentes demonstram que o uso precoce destes fármacos, 
tem a capacidade de alterar a história natural da doença a curto e a longo prazo, conduzindo à 
cura histológica. Estes dados contribuiram para a atual mudança de estratégia terapêutica no 
sentido top-down, ou seja, iniciar com fármacos mais agressivos e reduzir de intensidade 
consoante os resultados obtidos. 
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A abordagem top-down, frequente em doentes jovens, é pouco empregue em idosos não apenas 
por apreensão do perfil de efeitos adversos mas também porque o objetivo de cura da mucosa, 
um dos pilares do tratamento dos jovens, não é essencial no idoso. Assim, recomenda-se que a 
prescrição de biológicos em doentes idosos com DII seja adaptada à sua situação clínica, 
considerando o perfil de risco benefício e colocando a tónica no controlo sintomático.  
Doentes com DII ativa e que manifestem intolerância ou ausência de resposta aos 
immunosupressores e/ou agentes biológicos existentes estão limitados em termos de opções 
terapêuticas. Nestes casos, e exclusivamente para a colite ulcerosa, desenvolveu-se uma técnica 
de leucoforese designada de aferese selectiva de granulócitos e monócitos que tem demonstrado 
benefício clínico e um perfil de segurança aceitável. No entanto, são necessários estudos 
controlados e randomizados que clarifiquem a sua eficácia na CU geriátrica e assegurem a sua 
segurança nesta faixa etária.  
O tratamento cirúrgico está reservado para casos em que há falência da terapêutica médica ou 
perante complicações como a obstrução, fistulização, formação de abcessos, megacólon tóxico 
ou hemorragia.  
O aumento da incidência da DII a nível mundial assim como as limitadas opções terapêuticas 
existentes presentemente reforçam a importância da investigação nesta área. O estudo do 
microbioma intestinal e de como a sua desregulação pode desencadear a DII num indivíduo 
geneticamente predisposto e a análise molecular de proteínas imunoreguladoras presentes no 
trato digestivo, tais como as reguladoras da sinalização de proteínas G (RGS), são dois 
exemplos de campos de pesquisa com vista a identificar novos alvos terapêuticos.  
A DII é uma patologia crónica complexa dependente de factores genéticos, imunológicos e 
ambientais que requer uma abordagem especializada e multidisciplinar. Por outro lado, o doente 
idoso possui características específicas e uma fragilidade intrínseca, pelo que, na DII geriátrica, 
é de redobrada importância a necessidade de algoritmos de tratamento ao mesmo tempo 
adaptados e holísticos.  
Só a colaboração entre a rede de saúde primária, os médicos especialistas, o doente e a sua 
família permitirá otimizar a eficácia do tratamento e assegurar uma melhoria na qualidade de 
vida do doente idoso com DII. 
Do presente trabalho depreendemos que os estudos que suportam o conhecimento sobre a DII 
e o seu tratamento têm no geral um baixo nível de evidência científica. Numa subpopulação 
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com características especiais como a geriátrica, que frequentemente é excluída dos ensaios 
clínicos, a falta de evidência torna-se ainda mais evidente, o que dificulta bastante a decisão 
terapêutica neste grupo. 
Concluímos que a investigação nesta área deve ser aprofundada. Necessita um esforço 
internacional multicêntrico no sentido de os estudos efectuados serem de elevado nível de 
evidência científica e de os idosos estarem adequadamente representados nos ensaios clínicos, 
para que as conclusões sejam válidas e transponíveis para este grupo particular. Só nestas 
condições será possível a criação de normas de orientação apropriadas ao doente idoso. 
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Introduction:  
Inflammatory bowel disease (IBD) is a chronic, progressive disease of unknown aetiology 
characterized by a dysregulated immune response to host intestinal flora in genetically 
predisposed individuals.  
Statistics from the 2014 Portuguese population census demonstrate that the population over 65 
years of age is increasing rapidly. In merely five years this value rose from 18.3% to 20.3%, 
making the Portuguese population one of the oldest in Europe [1]. The significance of this 
demographic pattern is made obvious when one considers consumption of health resources and 
associated costs.  
The epidemiological transition model [2] shows that chronic conditions, a category in which 
inflammatory bowel disease (IBD) inserts itself, make up the larger share of the disease burden 
in developed countries [3]. Considering that these chronic conditions are more common in the 
elderly, and that they tend to coexist in this group it becomes clear that the optimization of care 
for such conditions is essential to reduce frailty and hence decrease acute care spending with 
the geriatric patient with IBD [4].   
IBD in the older population can be divided into two groups: one where the disease was 
diagnosed in an individual at a late age (late-onset IBD) and another so called long-standing 
IBD, where the diagnosis was made at a younger age [5].  
The definition of elderly IBD patients remains far from clear with ranges from 40 to 75 years 
old mentioned in the literature. Recent publications have employed the >60 and >65 cut-offs as 
defining of elderly-onset IBD but a consensus is lacking [5] [6] [7] .  
Approximately 10-15% of IBD cases are late-onset IBD diagnosed in people over the age of 60 
[6] [8]. Since IBD has a negligible impact on mortality, the pool of IBD patients over the age 
of 60 will be significant as we add the late-onset and the surviving long-standing IBD 
subgroups. There are considerable challenges to the management of elderly patients with IBD. 
These patients are commonly fragile, with multiple comorbidities that can not only delay and 
confound the diagnosis of IBD but also aggravate the course or complicate treatment of the 
disease.  
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Information for this review was obtained through searches on PubMed using the following 
keywords: inflammatory bowel disease (IBD), Crohn’s disease, Ulcerative colitis, elderly-onset 
IBD, late-onset IBD and long-standing IBD, epidemiology, pathophysiology, genetics, 
immunology, immunosenescence, environmental factors, gut microbiome, clinical 
presentation, differential diagnosis, therapy, aging. The review included editorials, case studies, 
narrative reviews, systematic reviews, meta-analyses and randomized controlled trials, from 
1980 to the present year.  
This review is intended to summarize the available literature relative to the differences and 
similarities between late-onset and long-standing IBD in terms of epidemiology, clinical 
presentation, prognosis and treatment as well as point out areas of knowledge where further 
investigation is need. The goal is to inform physicians and thereby allow them to tailor 
therapeutic strategies to the elderly IBD population under their care. 
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Epidemiology:  
It has been proposed that IBD follows a bimodal incidence pattern, with an incidence peak at a 
younger age and a second incidence peak later in life [9] [10] [11] [12] [13]. However, this 
pattern is far from consensual and several epidemiological studies have failed to demonstrate it 
since Loftus et al. 1998 [14] first questioned this data [8] [15] [16] [17] [18]. This discrepancy 
might have arisen because the initial studies demonstrating a bimodal distribution utilized more 
rudimentary diagnostic criteria for IBD, based on clinical observation or X-ray findings, with 
colonoscopy as an option not a mandate. Also, these studies were held in reference centres for 
the disease where the likelihood of selection bias is greater.   
With the aging of the present IBD patient population added to the patients who are diagnosed 
at a later stage, the number of elderly patients with IBD is on the rise. Allied to the fact that 
incidence of IBD appears to be increasing [19], clinicians will need to be prepared to handle 
increasingly complex geriatric patients.  
Currently, the global burden of IBD represents 0.5% of the general population. In Europe, there 
are approximately 2.5-3 million people diagnosed with this condition and the associated health 
costs are estimated to be € 4.6–5.6 billion annually [19]. Azevedo L.F (2010) developed a 
pharmacological approach to estimate the prevalence of IBD in Portugal where intestinal anti-
inflammatory drug (IAI) consumption as well as mean prescribed daily dose were analysed. Per 
this study, the prevalence of IBD in Portugal increased from 86 to 143 per 100,000 between 
2003 and 2007. UC prevalence rose from 42 to 71 and CD from 43 to 73 per 100,000 [20].  
Incidence figures for late-onset IBD lie somewhere in the interval of 10-15% of all IBD 
patients. [5]. A large population-based cohort study by Charpentier et al, 2014 determined that 
5% of Crohn’s disease (CD) and 11% of ulcerative colitis (UC) diagnoses were made in 
individuals aged over the age of 60 [6]. This same study demonstrated that among the IBD 
population studied, the proportion of CD was lower in the elderly-onset patients than in younger 
adults while the proportion of UC was higher.  
In Portugal, epidemiological data on elderly onset IBD are scarce and considering the Southern-
European regional differences in IBD incidence rates [21], mere extrapolation data may prove 
an inaccurate approach. Therefore, further studies are required to provide this incidence data as 
well as a phenotypic description of this subset of IBD as applies to this European country. 
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Clinical Presentation:  
Evidence regarding the clinical features of IBD in the elderly onset population is conflicting. 
Some studies state that late onset IBD has certain phenotypic characteristics that differ from 
long standing IBD in terms of severity, disease location and presenting symptoms [6] [22] while 
others state that there is a general similarity of features between these two groups [5]. The 
argument as to whether elderly-onset and long-standing IBD are in fact two genotypically 
different disorders, with their respective phenotype, is still unresolved [23].  
A milder course has been suggested [24] for the elderly onset patients, with lower utilization of 
immunosuppressants [25] and lower cumulative probability of surgery at 5 years in this group 
[6]. However, some authors suggest that the initial flare is more severe in the elderly-onset IBD 
subgroup [26].  
A point to consider when analysing seemingly conflicting results in disease severity is that the 
elderly patient is complex and therefore despite a milder disease course, disease flares can be 
conducive to higher rates of hospitalization, morbidity and mortality simply due to 
comorbidities that these patients possess [27]. Also, older-onset IBD is associated with 
increased rates of misdiagnosis owing to the wide range of differential diagnosis that must be 
considered in this age group, which contributes to a delayed diagnosis [7] and hence poorer 
outcomes.  
A large population-based cohort study by Charpentier et al presented data on the natural history 
of elderly-onset IBD. Regarding CD the study determined that elderly onset CD phenotype is 
more often inflammatory and rarely progresses to the stricturing or fistulizing behaviour. It´s 
location is commonly colonic or ileocolonic and as such symptoms of rectal bleeding and anal 
fistulas are less frequently reported [6].  
Elderly onset UC presents more often as left-sided or extensive disease and disease location 
tends to remain stable over time. Symptoms of rectal bleeding and abdominal pain are less 
common in the elderly cohort [6]. A family history is uncommon in both CD and UC of elderly 
onset, which points towards a larger influence of environmental factors in the disease aetiology 
over the genetic or immunological influence [28].  
Most studies demonstrate that the risk of extra-intestinal manifestations is similar between the 
elderly-onset and long-standing IBD populations [26] [29]. In patients over 60, approximately 
13% will develop an extraintestinal manifestations. The most common of these manifestations 
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is arthritis, followed by uveitis, spondylitis and erythema nodosum [15]. Arthritis in IBD is 
classified as a seronegative spondyloarthropathy, associated with a positive HLA-B27 genotype 
and occurs in up to 30% of IBD patients [30]. It is often divided into two categories, peripheral 
and axial arthritis, according to the joints involved. Peripheral arthritis can be subdivided into 
type I, a pauci/oligoarticular arthritis particularly affecting the larger joints of the lower 
extremities, and type II, a polyarticular arthritis of symmetrical distribution and affecting the 
upper limbs predominantly [31]. The axial pattern of distribution includes sacroiliitis, 
inflammatory back pain (IBP) and ankylosing spondylitis. Type I peripheral arthritis is acute in 
onset, correlates with IBD activity and tends to improve upon commencement of IBD-directed 
therapy. Type II peripheral arthritis and axial arthritis are independent of disease activity require 
specific treatment other than that initiated for IBD. NSAID’s, corticosteroids and analgesics are 
the three most commonly prescribed drug classes for the management of IBD arthritis. 
NSAID’s are particularly nefarious in the elderly patient. Pharmacokinetic and 
pharmacodynamic changes that occur in this age group increase the sensitivity of the patient to 
this drug class and lead to increased risk of cardiovascular, neurological, renal and hepatic side 
effects [32]. Therefore, prescribing for an elderly IBD patient must take into consideration the 
risk vs benefit ratio of each drug class employed.    
The following table shows the main clinical presentation differences between elderly-onset and 
long-standing IBD [6] [5]. 
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Table 1: Features of elderly-onset vs long-standing IBD. Note: adapted from Gisbert and 
Chaparro, Systematic review with meta-analysis: inflammatory bowel disease in the elderly, 
2013, Table 2 and Charpentier et al, Natural history of elderly onset inflammatory bowel 
disease: a population-based cohort study, 2013, Table 1 and 2.  
Characteristic Elderly Onset IBD Long-standing IBD 
Age at 
diagnosis 
>60 years of age, though there is no 
consensus as to the cut off age. This 
population accounts for 10-15% of 
all IBD cases.  
2nd to 4th decades of life is the most 
common age bracket at diagnosis, 
though paediatric cases account for 
10% of all IBD cases 
Presenting 
symptoms 
CD: less diarrhoea, abdominal pain 
and fever, but more rectal bleeding 
and anal fistula 
CD: weight loss, fever, abdominal 
pain and diarrhoea are common  
UC: less rectal bleeding and 
abdominal pain. More severe initial 
attack. 
UC: weight loss, rectal bleeding and 
abdominal pain. Usually less severe 
initial attack. 
Family history Uncommon Frequently present 
Location 
CD: colonic localization is more 
common. Disease location tends to 
remains stable.  
CD: ileo-colonic involvement, 
disease progression common.  
 
UC: mainly left-sided at diagnosis.  UC: left-sided or extensive disease 
at diagnosis. Proctitis is more 
common in this group. 
Clinical course 
CD: inflammatory behaviour is 
more common at diagnosis, with a 
less aggressive disease course.    
CD: more aggressive, with 
structuring and fistulising 
behaviours developing commonly   
UC: more favourable clinical course 
with less proximal extension over 
time 
UC: more aggressive, with greater 
proximal progression over time. 
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Differential diagnosis:  
IBD are frequently non-specific and allow for multiple diagnoses to be considered. The 
situation is further complicated should the patient in question be an elderly individual, in which 
conditions that mimic IBD are more common [7]. In the elderly-onset IBD subgroup, presenting 
symptoms are often indolent and atypical, with less abdominal pain, bleeding, systemic 
symptoms and extra-intestinal manifestation compared to younger IBD patients.  All these 
factors contribute to a delay in diagnosis of up to 6 years in older patients compared to 2 years 
in younger patients, with initial misdiagnosis rates of 60% compared to 15% in younger patients 
[33].  
The differential diagnosis of IBD is complicated in the elderly individual, in which conditions 
such as complicated diverticular disease, ischaemic colitis, infectious diarrhoea, microscopic 
colitis, NSAID colitis and colorectal cancer, that can mimic IBD, are more common [7]. 
Complicated diverticular disease can present with localized abdominal pain, rectal bleeding and 
diarrhoea, symptoms which overlap those of IBD. Diverticular disease may coexist with IBD 
and can also mimic CD of the colon, particularly in cases of fistulisation and perforation. Of 
particular interest is the so called segmental colitis associated with diverticular disease (SCAD), 
which can resemble IBD clinically, endoscopically and histologically [34].  
Ischaemic colitis is a large spectrum disease ranging from transient and self-limited mucosal 
and/or submucosal ischaemia to an acute, transmural infarction that may evolve to necrosis and 
death. It presents with abrupt onset of abdominal pain over the affected segment and stool 
mixed with blood. It most commonly affects elderly patients and due to its potential gravity, it 
must always be ruled out before pursing investigations for IBD [24]. 
Infectious colitis is an important diagnosis in the elderly population, not only due to the so-
called immunosenescence phenomenon [35] but also due to changes in the gut microbiota that 
occur in this age group [36]. It can be taken for IBD, especially UC and must be included in the 
differential diagnosis of patients with diarrhoea. Pathogens such as Campylobacter, 
Clostridium difficile, Eschericha coli O157:H7, Giardia lamblia, Histoplasma, Mycobacterium 
tuberculosis, Salmonella and Shigella can present similarly to IBD [37]. Of note, Salmonella 
and E. coli O157:H7 can both present with a more severe course in elderly patients and therefore 
require antibiotics considerably more often than their younger counterparts [38].  
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Clostridium difficile infection (CDI) has an increased incidence in IBD patients, particularly 
those on corticosteroids and immunomodulators [39]. On the other hand, as part of the 
immunosenescence process, the microbiome of the elderly patient is altered with increasing 
numbers of atypical Bacteroides and Clostridia species [40], facilitating the appearance of 
Clostridium difficile associated disease (CDAD). CDAD is much more severe in a patient with 
IBD [41], with increased rates of hospitalization and colectomy compared to non-IBD patients 
[42]. Therefore, CDI testing should be considered on all IBD patients with a disease flare and/or 
who are not responding to treatment.    
Microscopic colitis (MC) is an inflammatory disease of the bowel where patients present with 
chronic watery diarrhoea. Though appearing grossly normal on colonoscopy, histological 
analysis of the mucosa reveals two subsets of disease: collagenous colitis or lymphocytic colitis. 
The incidence of MC increases greatly with age [43] must be considered in the differential 
diagnosis of elderly-onset IBD.  
NSAID colitis is an intestinal inflammation secondary to NSAID intake, presenting with a wide 
variety of symptoms, from GI bleeding to abdominal pain, gastroduodenal ulceration and 
perforation that can mimic IBD. NSAID can not only precipitate flares of UC and CD but also 
this drug class is often required in IBD patients for the treatment of other comorbidities or for 
pain relief from axial IBD arthritis and hence ceasing it is not always simple. Therefore, a 
thorough review of the patient’s regular medications is essential and a trial of cessation can be 
employed where doubt remains as to the cause of the symptoms.  
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Cancer and IBD: 
Elderly IBD patients are at an increased risk of developing several types of cancer when 
compared to the general population [44] and therefore warrant close surveillance and a full 
screening before starting any immunosuppressant therapy [45].  
Though past data regarding the risk of colorectal cancer (CRC) in IBD patients was conflicting, 
recent meta-analyses have clarified that there is in fact an increased risk in this population [46] 
[47]. The risk for developing CRC appears larger in UC, with a standardized incidence ratio of 
2.4 compared to 1.9 for CD [46] [47]. Male sex, younger age at diagnosis and extensive colitis 
were determined to be significant risk factors [47]. CRC diagnosis is made at a younger age in 
IBD patients but there has been no consistent demonstration of increased mortality in the IBD 
population group [47]. 
A recent population-based study by Cheddani et al demonstrated that there is no increased risk 
of CRC in elderly-onset IBD patient within the 6-year follow-up window of the study [48]. 
Therefore, further studies with longer follow-up times are required to validate these results. 
Current ECCO Consensus Statements on Inflammatory Bowel Disease and Malignancies 
recommend endoscopic surveillance tailored to the patient’s risk profile [45]. Risk factors to 
consider include duration of disease, extension, severity, presence of primary sclerosing 
cholangitis and family history of CRC. Of note, the extent of inflammation of the colon is the 
best established risk factor, such that CRC risk is highest in pancolitis [49].   
Drugs commonly used in the treatment of IBD have been associated with increased risk of 
malignancy, namely immunomodulators and biologics. The use of these medications in the 
setting of chronic inflammation (which characterizes IBD) generates concerns regarding their 
contribution to increased risk of IBD-related cancers [50].  
There are reports of thiopurine-related urinary tract [51] and thyroid cancers as well as 
melanoma in IBD patients [50]. Also, thiopurine use and increasing age have both been linked 
to increased rates of non-melanoma skin cancers (NMSC) [52].  
Furthermore, thiopurine exposure was associated with a three- to fivefold increased risk of 
lymphoma [53], particularly in older IBD patients.  These thiopurine-associated lymphomas 
are typically caused by the reactivation of a hereto latent Epstein Barr virus (EBV) infection 
[54]. Anti-TNF agents infliximab and adalimumab have also been linked to increased risk of 
malignancy, namely melanoma and lymphoma [55] [7]. However, several case-control and 
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cohort studies have suggested that these agents in monotherapy do not increase the risk of 
cancer in IBD patients [45]. All in all, the evidence available seems to suggest no increased 
long-term cancer risk of anti-TNF agents in IBD patients [56].  
Apart from medication there are other IBD-specific factors such as early disease onset, male 
gender and age > 65 which also contribute to increased risk of malignancy, particularly 
haematological cancers and that must be considered when analysing the patient’s risk profile 
[45].  
Management of IBD patients with a history of cancer can be difficult. Immunosuppression has 
been associated with increased recurrence of cancer [57] and therefore controlling active IBD 
with immunomodulators can prove problematic. Biologicals remain unclear in terms of safety 
in IBD cancer patients, not only in terms of risk of tumour growth but also in terms of 
pharmacological interactions, especially in elderly individuals who are often excluded from 
clinical trials pertaining to this drug class [25] [58]. The ECCO Consensus Statements suggest 
multidisciplinary management of IBD cancer patients and cessation of thiopurines, calcineurin 
inhibitors and anti-TNF agents until cancer therapy is completed.  IBD flares in patients with a 
history of cancer can be managed with 5-aminosalicylates and/or local corticosteroids. More 
severe flares can be addressed with methotrexate, anti-TNF and short-term systemic 
corticosteroids [45].  
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Morbidity and Mortality:  
The elderly are increasingly prone to comorbidities such that 20% of patients aged ≥65 years 
have at least 5 chronic conditions [59]. This reality not only undermines their performance 
status but also helps to perpetuate a state of frailty. A recent retrospective observational study 
has reported that elderly IBD patients suffer most commonly from cardiovascular or pulmonary 
disease as well as diabetes mellitus. Among the geriatric IBD patients, 33.8% had coronary 
artery disease (CAD), 22.6% with chronic lung disease, 22.6% with congestive heart failure 
and 18.8% with diabetes mellitus [60]. A direct implication of this fact relates to the risk of 
polypharmacy and the iatrogenic effects derived therefrom. This same study went on to 
determine that the average number of medications taken on a regular basis by an elderly IBD 
patient was 7 ± 3.5 and that 21% of this patient population had major polypharmacy.   A known 
consequence of polypharmacy is prescribing cascades where, to relieve symptoms that are in 
fact due to adverse drug interactions, a new agent is commenced. To avoid this, constant update 
of medication sheets is needed, with removal of all unnecessary agents and simplification of 
drug regiments [35]. 
  
Older patients with IBD are in themselves a high-risk group. When hospitalized they have a 
higher mortality rate than younger patients, even after adjusting for comorbidities and the 
presence of complications [61] . Age therefore appears to be an independent risk factor for 
adverse events in IBD [62]. If further studies come to validate this finding, the creation of 
guidelines specific for elderly IBD patients becomes even more relevant in an attempt to reduce 
mortality by targeting age as a risk factor.  
 
Geriatric IBD patients also demonstrated increased incidence of thromboembolic events, with 
hypercoagulability and subsequent thrombosis complicating 3% of all IBD-related admissions 
[63, 64]. However, overall mortality of UC patients is not higher than that of the general 
population and in CD, its effect on mortality remains controversial.  
 
In terms of surgical outcomes, older patients had a longer post-operative stay than younger 
patients which might suggest increased incidence of complications, especially cardiovascular 
and pulmonary [65] [27]. Interestingly, older patients were less likely to undergo surgery and 
therefore one must consider whether comorbidity and the presence of complications may be 
preventing these patients from being good surgical candidates [61]. Exceptions to this were 
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older patients presenting with fistulising or stricturing disease who were more likely to proceed 
to surgery than younger cohorts. These disease phenotypes may be less tolerated in the elderly 
and therefore not amenable to conservative medical management.  
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Treatment considerations: 
Age associated variables that influence the management of IBD:  
Polypharmacy and potential medical interactions:  
As previously stated, the medical management of IBD in the elderly is often complicated by 
comorbidities that generally imply complex drug regiments and increased risk of 
pharmacological interactions.  The state of being elderly is in itself a risk for these adverse 
effects due to changes in physiology which significantly affect pharmacokinetics and 
pharmacodynamics.  As body fat increases and total body water, extracellular volume and lean 
muscle mass decrease, distribution volumes of both hydrophilic and lipophilic drugs are 
affected and hence require adjustment [35] [66]. Drug clearance is affected not only by reduced 
glomerular filtration rates but also reduced splanchnic and hepatic vascular flows that occur 
with aging [67]. Also to bear in mind are the age-associated changes in circulating plasma 
proteins that inherently influence the levels of protein-bound drugs. Therefore, conventional 
dosing regiments will mostly likely require age-based adjustments and prescribing should 
follow the “start low and go slow” approach [5].  
Nutritional deficiencies:   
Elderly patients with IBD are frequently deficient in vitamin B12, vitamin D and iron [68]. In 
elderly-onset CD, increased disease duration was correlated with the presence of the above 
mentioned nutritional deficiencies but no such correlation was found for geriatric UC [60].  
Elderly patients with IBD are commonly protein deficient, with protein energy malnutrition 
(PEM) occurring in 20-85% of these patients [68]. These findings reinforce the importance of 
repeated nutritional assessments, especially in patients with longer duration of IBD.   
Comorbidity:  
Pre-existing comorbidities may influence medication regiments used to treat an elderly 
patient’s IBD. For example, the use of corticosteroids in diabetic patients may be limited by the 
risk of developing hyperglycaemia, hyperlipidaemia and hypertension.  Besides the risk of 
serious infection, other adverse effects of chronic corticosteroid use include cataracts, 
glaucoma, depression and osteoporosis [66]. Also noteworthy is the recommendation to avoid 
anti-TNF agents in patients with class III and IV congestive heart failure and central 
demyelinating diseases [69]. Infliximab for instance interacts with sulfonylureas, simvastatin, 
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and pain medication such as tramadol and fentanyl, agents prescribed for common 
comorbidities such as hypercholesterolemia, pain and diabetes [66]. These are but three 
examples that signal the need for coordination of care across medical specialties and 
personalization of drug regiments to the patient at hand.   
Immunosenescence:  
Aging is associated with decreased immune function in a process called immunosenescence. 
There is thymic atrophy with decreased T cell production and functionality. Primary 
lymphopoiesis is reduced as evidenced by decreased T and B cell bone marrow progenitors. 
Imbalances between Th1 and Th2 responses as well as reduced naïve T cell populations lead to 
increased risk of viral infection and malignant disease [70]. Decreased bone marrow production 
of B cell clones and antibody-forming cells has many effects ranging from decreased tumour 
immunosurveillance to increased susceptibility to infection and reduced response to vaccines. 
A theory correlating B cell immunosenescence to elderly-onset IBD suggests that, because 
antibody production at the level of the intestinal mucosa is important in maintaining barrier 
function and regulating bacterial flora, age-associated impairment of antibody production could 
contribute to IBD development [23]. However, no direct evidence of the link between B cell 
immunosenesce and IBD is yet available. The innate immune system is also affected by the 
aging process [71]. Neutrophils have reduced superoxide production and their capacity for 
phagocytosis is reduced [72]. Dendritic cells suffer changes related to their maturation, with 
decreased threshold of activation, altered profile of cytokine secretion and decreased antigen 
uptake. Macrophages have reduced phagocytic capacity and secrete larger amounts of pro-
inflammatory cytokines [71]. These changes are likely due to the altered hormonal and cytokine 
milieu present in the elderly and may contribute to an increased incidence of inflammatory 
diseases [73].  
The mucosal immune system is not spared from senescence. Mucosal-associated lymphoid 
tissue (MALT) becomes scarcer with age, with reduced lymphoid follicle development and 
associated antibody production. These changes determine a decreased intestinal barrier function 
as the levels of IgA, an immunoglobulin involved in mediating host-microbiome interactions, 
drop with MALT depletion.  
‘Inflammaging’ refers to a chronic low grade inflammation present in elderly individuals due 
to dysregulated release of cytokines into the bloodstream [35]. In fact, the balance between pro- 
and anti-inflammatory cytokines can be used to determine a patient’s risk profile for frailty and 
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mortality [74]. This process together with changes in the microbiota associated with aging may 
affect the clinical course of IBD due to abnormal immune responses and decreased mucosal 
tolerance.   
Though changes in the immune system with age are well established, how these changes impact 
IBD and its phenotype through the age groups is still not known.  
Therapeutic endpoints: 
Treatment in IBD aims to achieve disease remission with both symptom resolution and mucosal 
healing [35]. Histologic resolution is not a target per recent consensus recommendations [75]. 
Biomarkers such as CRP and faecal calprotectin are to be used in the monitoring of IBD patients 
but are not targets for treatment in themselves. These recommendations apply to both long-
standing and elderly onset IBD patients. However, the goal of remission can be unattainable in 
elderly patients not only due to their comorbidities but also compliance issues, polypharmacy 
and adverse reactions, among other limitations. This is especially true for deep mucosal healing 
which often requires a combination of immunosuppressants too aggressive for frail patients to 
tolerate. Therefore, tailoring treatment targets for elderly IBD patients may be necessary and 
can include simplification of treatment regiments with awareness of cost, mindfulness of 
potential drug interactions and strategies to improve quality of life which tackle particularly 
distressing symptoms such as incontinence, frequent stooling and pain [66].  
Medical therapy: 
Medication prescription patterns vary between younger and elderly IBD patients as the 
perceived limitations of the latter population group influence the clinician’s decision. Several 
studies have demonstrated that sulfasalazine and corticosteroids are the most commonly 
prescribed medication classes in the elderly patient, with the biological and immunomodulators 
being prescribed significantly less frequently [8] [76].  Reasons for this could be due to the 
perceived milder disease course of elderly onset IBD and hence lesser need for strong 
immunosuppressant medication and the increased concern over adverse effects of the more 
aggressive medications in the older patients [77].  
The choice of treatment depends on factors such as disease severity, location, extension, 
response to previous treatment schemes, comorbidity, use of concurrent medications and 
patient compliance. 5-Aminosalicylates are generally taken to be safe and effective medications 
for the treatment of mild to moderate UC while for Crohn´s disease their action remains 
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equivocal [78]. Despite this, 5-ASA use is widespread among elderly CD patients probably due 
to its favourable side effect profile [6]. All forms of these medications seem to be equally 
effective but it is important to consider that the elderly patient may lack the dexterity to correctly 
perform enemas or apply suppositories and situations of incontinence reduce the effectiveness 
of these methods. Oral dosing regimens should be simplified to once-daily prescriptions which 
have been proven to be of similar efficacy to split-dosing regimens [79]. 5-ASA nephrotoxicity 
has been reported in the literature [80] and though there is little evidence evaluating the use of 
these drugs in renal-impaired patients, caution is recommended when prescribing for this 
population group.  
Corticosteroids are used not only in remission induction but also as long term maintenance 
therapy in the elderly population group despite the known corticosteroid complications [81]. 
Of note, elderly-onset IBD patients receive higher and more frequent doses of corticosteroids 
at diagnosis than patients who were diagnosed at a younger age [60]. Continual treatment with 
corticosteroids without an exit strategy can lead to increased mortality in IBD patients [82] and 
therefore chronicity should be avoided. Budesonide has a more favourable side effect profile 
than other glucocorticoids due to localized drug delivery and a high first pass metabolism which 
reduce systemic bioavailability [83]. Therefore, it is commonly used as induction therapy in 
patients with mild to moderate ileal or ileocecal disease [84]. However, budesonide has been 
linked to endocrine disturbances such as Cushingoid features and hypokalaemia as well as 
dyspepsia, behavioural changes, cutaneous reactions, menstrual changes and palpitations [85] 
which, though less common than for other glucocorticoids, are significantly more so than with 
placebo. As with other medications, corticosteroid clearance is decreased in older patients 
which increases the risk of drug interactions. Phenytoin, rifampicin, phenobarbital and 
ephedrine are inducers of cytochrome enzymes and therefore decreased the systemic levels of 
corticosteroids while inhibitors of these enzymes produce the opposite effect [86]. This 
pharmacological class is known to cause both dependency and tolerance which increase the 
need for immunosuppressant therapy. Corticosteroid dependence is particularly common in 
elderly individuals who are in themselves vulnerable to the complications of 
immunosuppression hence reinforcing the need for steroid-sparing strategies in maintenance 
regimens.  
Among the many immunomodulator drugs in existence, azathioprine (AZA), 6-mercaptopurine 
(6-MP) and methotrexate (MTX) are the three most commonly used in the treatment of IBD. 
The thiopurines AZA and 6-MP are effective for induction and maintenance of remission and 
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no difference has been found in terms of efficacy and toxicity of these agents between elderly 
and younger IBD patients [15]. Among the side effects of thiopurines are idiosyncratic reactions 
such as rash, pancreatic and hepatitis and dose-dependent myelotoxicity and hepatotoxicity. In 
prevention of the latter two effects, regular monitoring with a full blood count and liver profile 
are essential. Allopurinol has an interesting effect over thiopurine metabolism. It not only 
inhibits xanthine oxidase and therefore interferes with a thiopurine catabolism pathway 
mediated by this enzyme [87] but also in patients who preferentially metabolise 6-MP to methyl 
mercaptopurine, allopurinol can be used to circumvent this hypermethylation pathway and 
therefore reduce drug toxicity. However, this potentially beneficial effect is offset by the 
findings of infectious complications in elderly IBD patients treated concomitantly with 
immunomodulators and allopurinol [88]. Methotrexate can be used for induction and/or 
maintenance therapy for CD in patients intolerant to AZA or 6-MP or who are steroid dependent 
or refractory. Known adverse effects include bone marrow suppression, hepatic fibrosis, 
alopecia and gastrointestinal toxicity. MTX has renal excretion and therefore age-related 
changes in kidney function must be investigated before prescribing this drug to an elderly IBD 
patient. It is important to note that NSAID´s and penicillin interact with MTX by reducing its 
excretion and therefore increasing toxicity.   
Anti-TNF agents, also called biological agents, are used in the treatment of moderate to severe 
UC and CD, both in induction and maintenance of corticosteroid-free remission. Studies have 
shown that an earlier initiation of these agents, with their potential for mucosal healing, can 
improve outcomes for IBD patients both in the short and in the long-term [89] [90]. These 
findings support a top-down approach in treatment management as opposed to the conventional 
step-up currently in practice. However, though the former approach is being employed by many 
gastroenterologists in the treatment of younger patients, recent evidence demonstrates underuse 
of biologicals and immunomodulators in the elderly population, with preference for 5-ASA and 
corticosteroid prescription and hence a bottom-up approach [6] [60] [76]. Reasons for this 
include concerns about the safety and efficacy of the stronger immunosuppressant agents in the 
older IBD cohort, especially the risk for infectious complications, drug interactions and 
malignancy. Though still sparse, the data from past trials seems to suggest that biologicals are 
effective to use in older patients [91]. However, the data also suggests an increased risk of 
infection and mortality when compared to the younger patients or patients of the same age 
group who did not receive biologicals [92] [93]. At present, the prescription of biologicals for 
an elderly IBD patient must be tailored to their clinical picture in that the benefit obtained from 
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disease activity control must outweigh the risks associated with this therapy, which may be 
greater in this age group.      
Antibiotics are utilized as adjuncts to medical therapy in IBD patients. In situations of pouchitis, 
fistulizing CD, CD-related abscesses and fulminant colitis, metronidazole and ciprofloxacin are 
frequently used. Metronidazole has several adverse effects which include neuropathy, metallic 
taste and nausea [22] [94], all three of which are more common in the elderly patient. Moreover, 
its inhibitory effect over cytochrome enzymes increases the bioavailability of drugs such as 
calcium channel blockers, simvastatin and sildenafil [94]. Other side effects include increased 
lithium toxicity, potentiation of warfarin action with prolonged INR and disulfiram reaction 
when taken with alcohol. Ciprofloxacin has several drug-to-drug interactions due to its 
inhibitory influence over cytochrome enzymes [95]. It decreases theophylline clearance, 
increases warfarin levels and as a fluoroquinolone has the potential to increase the QTc interval.   
Surgical therapy: 
Surgical therapy is usually reserved for cases where medical treatment has failed or 
complications such as obstruction, fistulisation, abscess formation, toxic megacolon and 
intractable bleeding occur. For CD, there appears to be a decreased need for surgery in the 
elderly-onset IBD population group [96]. Risk factors for surgery in elderly patients include 
ileocolonic disease as well as structuring and penetrating disease behaviour [6]. Recurrence 
rates of CD after bowel resection are disparate between studies, ranging from a five-fold 
increase in risk in elderly patients to equal rates between age groups [97] [64] . One study 
demonstrated lower recurrence rates for elderly patients with CD although the time for 
recurrence was shorter than for younger patients (3.7 vs. 5.8 years) [98]. Overall, the prognosis 
of elderly-onset CD appears to be more favourable probably because the disease phenotypes 
more common in this age group are those associated with decreased risk of disease recurrence, 
namely less small bowel involvement and decreased penetrating disease.  There is a lack of 
evidence regarding prophylaxis of recurrence in the elderly population and therefore 
recommendations on this matter are lacking.  
For UC, surgical treatment is curative and is commonly performed in cases of colonic dysplasia 
or medically refractory disease. As in CD, elderly UC patients were less likely to undergo 
surgery compared to younger UC patients [99]. At time of diagnosis there was no significant 
difference in the requirement for colectomy between early and late-onset UC patients [100]. 
Proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the preferred surgical technique 
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for most patients. This procedure is usually performed in two steps, firstly total colectomy with 
pouch formation and diverting ileostomy followed by ileostomy reversal 6 to 12 weeks later. A 
permanent end ileostomy is also an option for patients where IPAA is not recommended. The 
decision between surgical treatment or intensification of medical therapy in an elderly patient 
is influenced by the fact that age is an important risk factor for postoperative morbidity and 
mortality. Apart from advanced age, hypoalbuminemia and male gender are also considered 
predictors of poor surgical outcome in IBD patients [60]. A recent study analysing the American 
College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) dataset 
demonstrated that the elderly had a 5- to 10-fold increase in 30-day mortality after IBD-related 
surgery compared with young patients [101]. These results highlight the need for pre-operative 
management of comorbidities and patient optimization followed by scrupulous postoperative 
monitoring. Several studies comparing surgical techniques in younger and elderly patients have 
shown similar complication rates between these age groups. One retrospective cohort study 
compared small bowel resection, total and partial colectomy, laparoscopic total and partial 
colectomy and stricturoplasty and found no statistically significant increase in complication 
rates in older patients. Proctocolectomy with IPAA compared to proctocolectomy with 
ileostomy has similar surgical morbidity in younger and older IBD patients such that at present, 
the consensus is that age is not in itself an exclusion criterion for IPAA [102] [103] [104]. 
Functional outcomes after pouch surgery are in general encouraging in elderly patients though 
there appears to be a greater incidence of diurnal incontinence and nocturnal leakage among 
patients aged >65 [15]. Despite this fact, 89% of elderly UC patients stated that they would 
undergo IPAA again and 96% would recommend the surgery to others [102]. Therefore, the 
decision between IPAA and ileostomy must rely on careful patient selection with good anal 
sphincter function and adequate cognition being crucial for pouch success [7] [104].  
 
Nutrition:  
The link between diet and onset and/or exacerbation of inflammatory bowel disease has been 
studied extensively. Conclusions regarding prevention strategies include encouraging diets rich 
in fruits, vegetables and n-3 fatty acids and low in n-6 fatty acids, with less importance placed 
on the carbohydrate content of the diet [105]. Micronutrients remain a topic of considerable 
debate as randomized clinical trials which evaluate their influence in IBD prevention and 
remission are lacking. So far, the evidence available points to beneficial effects of vitamin D 
and zinc in the prevention of CD but not UC [106] [107].  
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The understanding that prevails in the scientific community is that there is no IBD diet that can 
promote remission of active disease.  During disease flares the recommended nutritional plan 
should be adapted to the patient’s clinical condition taking into consideration the capacity for 
oral intake, the absorptive capacity of the GI tract, specific nutritional deficits detected and 
therapeutic goals (supportive care, treatment of malnutrition or induction and maintenance of 
remission) [105].  
IBD patients are at considerable risk of malnutrition as the disease process undermines normal 
nutrient absorption. CD poses a higher risk than UC because it can involve any part of the 
gastrointestinal system whereas UC is localized to the colon. Estimates suggest that 65-75% of 
CD and 18-62% of UC patients suffer from malnutrition [108]. The elderly are in themselves 
at increased risk of malnutrition due to a combination of physiological, social and economic 
factors. A mnemonic consisting of 9 D’s is frequently used to aid in the identification of risk 
factors: dementia, dysgeusia, dysphagia, diarrhoea, depression, disease, poor dentition, 
dysfunction, and drugs [109]. As practitioners charged with the holistic care of elderly IBD 
patients, we must actively search for possible nutritional deficits and liaise with dietitians to 
improve nutritional therapy and avoid nutrition-related disorders.  
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Future perspectives:  
Environmental factors: 
The faecal microbiome and its dysregulation in inflammatory bowel disease are topics of active 
research. IBD results from a complex interplay of environmental, immunological and genetic 
factors. Part of the disease process is thought to stem from dysregulated immune system 
activation against commensal microbiomes with loss of tolerance to intestinal antigens and 
consequent gut inflammation. Improved DNA and RNA sequencing techniques have allowed 
the identification of the microbial composition of the gastrointestinal tract. Consequently, the 
correlation between changes in microbial diversity and pathological states such as IBD is now 
clear and therapies aimed at restoring eubiosis are in development.  
Faecal microbiota transplantation involves the transfer of a suspension of liquid faeces from a 
healthy donor to a diseased recipient. Though it has proven to be very successful in the short-
term management of recurrent Clostridium difficile infections its use in IBD is still under 
investigation. A recent systematic review of 18 studies where FMT was performed on IBD 
patients (9 cohort studies, 8 case reports and 1 RCT) demonstrated a 45% clinical remission 
rate post-transplantation (36.2% when excluding case series to reduce publication bias). In 
subgroup analysis, this value dropped to 22% in UC patients and 60.5% in CD [110]. Though 
there appears to be a more favourable response in CD, further studies are needed to support 
this. Furthermore, issues such as donor selection, means of administration (i.e. nasogastric or 
nasoduodenal tube, colonoscope, enema or capsule), timing and frequency (use during flares or 
as maintenance therapy, as a single dose therapy or multiple doses) as well as long-term safety 
remain to be answered [111]. Therefore, due to the emerging nature of FMT, there is still 
insufficient evidence to support the inclusion of FMT in the armamentarium of treatment 
options for IBD.  
Probiotics are live, non-pathogenic organisms prescribed with the aim of restoring microbial 
balance in the GI tract. They are thought to act by lowering intestinal pH, inhibiting colonization 
and mucosal invasion by pathogenic microorganisms as well as regulating the immune response 
of the host. Probiotics containing Escherichia coli Nissle 1917 or VSL#3, have shown efficacy 
in patients with mild to moderate UC for the induction of remission [112] [113]. Despite these 
promising results, further studies are required to characterize effective strains, determine the 
appropriate dosage and frequency of administration as well as long-term safety. VSL#3 has 
also been demonstrated to decrease the onset of pouchitis [114] and therefore is now indicated 
for the prevention and maintenance of remission of this clinical entity.  
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Genetics: 
The genetic contribution to elderly-onset IBD remains unclear. However, the lack of family 
history in elderly-onset IBD could imply that the influence of genes is greater in long-standing 
IBD than in the older subset [23]. Genome-wide association studies (GWAS) have so far 
contributed to identifying over 99 genetic risk loci, and understanding the biological pathways 
these loci mediate is crucial to comprehending IBD pathophysiology. The goal of creating a 
genetic risk profile panel that can be applied to clinical practice to determine a patient’s 
probability of developing IBD or, if it is a patient with a diagnosis of IBD, a panel to determine 
the risk of developing severe disease, remains to be reached and further studies are needed 
before we can achieve it. Furthermore, it is known that genetic traits can be used to determine 
how a patient will respond to a specific treatment (e.g. 6-mercaptopurine response) [115]. 
Therefore, should this knowledge become applicable in practice, therapy can be truly 
personalized to the patient’s sensitivity profile thereby reducing adverse effects and increasing 
efficacy.  
Identifying a causal gene for IBD seems unlikely due to the complex interplay between 
environmental, genetic and microbial factors involved in the pathophysiology of the disease. 
However, through genetic models analysing defects arising from loci associated with IBD, new 
targets for diagnostics and directed gene therapy could arise [116].  
Immunology: 
Serological immune markers for CD include anti-Saccharomyces cerevisiae antibodies (ASCA) 
IgG, ASCA IgA, perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), anti-outer 
membrane porin of Escherichia coli (OmpC), pseudomonas anti-I2, flagellin (anti-Cbir1) and 
several glycans (chitobioside, laminariboside and mannobioside) [117]. For UC, there is fewer 
knowledge on the clinical utility of serum markers except for p-ANCA and anti-CBir1, which 
have been correlated with increased risk of pouchitis after colectomy [118]. There is no 
evidence validating the use of these markers in elderly-onset IBD and therefore investigation 
on the topic is needed.   
The development of biomarkers is a crucial area of investigation. Research on metabolome 
biomarkers, which can typify microbiome activity, and proteomic technology for identification 
of biomarkers is ongoing [119]. Though at present their inclusion in clinical practice is not 
feasible, in the future, as the aetiology of IBD is clarified, the biomarkers discovered may be 
integrated into a molecular diagnostic and prognostic tool.  
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An interesting area of research within molecular drug design involves regulators of G-protein 
signalling proteins (RGS) and their role in modulating intestinal inflammation [120]. RGS have 
been implicated in the modulation of opioid, cannabinoid and serotonin G-protein response to 
extracellular stimuli. In the GI tract, they serve as a promising target to reduce the severity of 
IBD by curbing the immunological pathways involved in intestinal inflammation. Though still 
in its commencement, this research is opening the field for the discovery of novel anti-IBD 
drugs at a time when the increasing incidence of IBD coupled with the known issues of the 
pharmacotherapy available are of major concern [19].  
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Conclusion: 
In the present work, evidence relating to the differences between elderly-onset and long-
standing IBD have been expounded. From this, the question arises as to whether they may in 
fact represent two different diseases within the spectrum of inflammatory bowel disease, with 
differing pathophysiological pathways determining timing of occurrence. It seems unlikely that 
onset of disease is simply a random event because of the clinical heterogeneity present between 
age groups (if it were, one would expect a similar phenotype irrespective of age of onset). The 
body of evidence pointing to differing mechanisms at play across the ages is growing, with 
genetic, immunologic and environmental contributions to aetiology being analysed and 
determined. As of yet, the factors determining age of onset remain unknown. However, the 
continued study of immunosenescence and its influence on the intestinal microbiome in IBD 
disease models may elucidate on the aetiological mechanisms at play.  
IBD in the elderly, be it long-standing or elderly-onset, presents many challenges to the caring 
physician. From differential diagnosis to treatment and long-term patient management, the 
older IBD patient differs from the young and requires a tailored approach with deviation from 
conventional practice algorithms. Only through cooperation between the primary health care 
network, specialist practitioners, the patient and his family will optimization of treatment 
efficacy and improvement in the quality of life of the elderly IBD-patient be possible.  
Though the paradigm of step-up treatment is changing towards more aggressive disease control 
earlier on in disease presentation, this is far from being implemented in the older patient cohort 
from fear of comorbidities and adverse reactions. A clinical distinction of fit vs frail elderly 
may assist in the decision process in that the former should be granted access to newer therapies 
and not be excluded simply due to an age criterion.  
The studies upon which current knowledge on IBD is based upon are, in general, of inferior 
levels of evidence. The elderly are a subpopulation that are all too often excluded from clinical 
trials, resulting in lack of evidence specific to this age group and thereby complicating the 
therapeutic decision making process. Therefore, further investigation is warranted to empower 
the creation of evidence-based guidelines for the management of this population group. An 
international multicentric effort is required to guarantee that the research being carried out is of 
the highest level of evidence and that the elderly are adequately included in clinical trials. Only 
in these conditions will the development of therapeutic guidelines adapted to the elderly patient 
be feasible. 
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